HEIDELBERG PHARMA AG (HPHA.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:HPHA - DE000A11QVV0 - Common Stock
HPHA.DE Key Statistics, Chart & Performance
The current stock price of HPHA.DE is 2.77 EUR. In the past month the price decreased by -9.62%. In the past year, price increased by 15.1%.
HPHA.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 70.86 | 46.60B | ||
| 1AE.DE | ARGENX SE | 72.08 | 47.40B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.78B | ||
| ABVX.PA | ABIVAX SA | N/A | 9.06B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.79B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.82B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.82B | ||
| 5CV.DE | CUREVAC NV | 7.46 | 974.09M | ||
| NANO.PA | NANOBIOTIX | N/A | 958.52M | ||
| IVA.PA | INVENTIVA SA | N/A | 731.60M | ||
| 6IV.DE | INVENTIVA SA | N/A | 678.11M | ||
| PHIL.MI | PHILOGEN SPA | 20.09 | 669.60M |
Related stock screener links
About HPHA.DE
Company Profile
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 114 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.
Company Info
HEIDELBERG PHARMA AG
Schriesheimer Strasse 101
Ladenburg BADEN-WUERTTEMBERG DE
Employees: 114
Phone: 49620310090
HEIDELBERG PHARMA AG / HPHA.DE FAQ
Can you describe the business of HEIDELBERG PHARMA AG?
Heidelberg Pharma AG is a biopharmaceutical company, which engages in the research and development of drugs for cancer patients. The company is headquartered in Ladenburg, Baden-Wuerttemberg and currently employs 114 full-time employees. The company went IPO on 2006-11-13. The firm focuses on the research and development of therapy treatments for oncology area. The company aims at applying toxin Amanitin into cancer therapies using its Antibody Targeted Amanitin Conjugate (ATAC) technology. The Company’s pipeline includes a number of drug candidates, such as HDP-101, a B-cell maturation antigen ATAC for multiple myeloma; PSMA-ATAC, prostate-specific membrane antigens, and CD19-ATAC, a B-lymphocyte antigen. Through partnerships, the Company develops clinical assets, including MESUPRON, REDECTANE and RENCAREX. The company also offers preclinical contract research services.
What is the current price of HPHA stock?
The current stock price of HPHA.DE is 2.77 EUR. The price decreased by -1.77% in the last trading session.
Does HPHA stock pay dividends?
HPHA.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of HPHA stock?
HPHA.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What do analysts say about HEIDELBERG PHARMA AG (HPHA.DE) stock?
8 analysts have analysed HPHA.DE and the average price target is 4.59 EUR. This implies a price increase of 65.7% is expected in the next year compared to the current price of 2.77.
How many employees does HEIDELBERG PHARMA AG have?
HEIDELBERG PHARMA AG (HPHA.DE) currently has 114 employees.
Can you provide the market cap for HEIDELBERG PHARMA AG?
HEIDELBERG PHARMA AG (HPHA.DE) has a market capitalization of 129.58M EUR. This makes HPHA.DE a Micro Cap stock.
HPHA.DE Technical Analysis
HPHA.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to HPHA.DE. HPHA.DE has a bad profitability rating. Also its financial health evaluation is rather negative.
HPHA.DE Financial Highlights
Over the last trailing twelve months HPHA.DE reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS decreased by -35.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -48.43% | ||
| ROE | -248.59% | ||
| Debt/Equity | 3.47 |
HPHA.DE Forecast & Estimates
8 analysts have analysed HPHA.DE and the average price target is 4.59 EUR. This implies a price increase of 65.7% is expected in the next year compared to the current price of 2.77.
For the next year, analysts expect an EPS growth of -44.19% and a revenue growth -15.81% for HPHA.DE